Chemomab Showcases Promising Results for Nebokitug at BSG Live’25
At the recent BSG Live’25 conference, Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) unveiled exciting data from its Phase 2 SPRING trial concerning nebokitug, a novel treatment targeting primary sclerosing cholangitis (PSC). This oral presentation highlighted the robust clinical potential of nebokitug, leading discussions on its advancement to the Phase 3 trial stage.
Results of the SPRING Trial
Presented by Dr. Douglas Thorburn, this vital trial showcases nebokitug's ability to provide significant health benefits for PSC patients. The data indicates that the treatment is both safe and well-tolerated over a 48-week period, notably improving multiple fibrotic and inflammatory biomarkers. These factors are indicative of slowing the progression of the PSC disease, a progressive and often life-threatening liver condition.
A Positive Outlook for PSC Treatment
Dr. Thorburn emphasized that PSC has long been a challenging condition to treat, with few effective therapies available. The data from the SPRING trial's double-blind, placebo-controlled portion revealed that patients receiving nebokitug displayed significant, dose-dependent improvements in anti-inflammatory and anti-fibrotic effects. Patients with more active forms of the disease specifically saw promising advancements in their overall health.
Prolonged Benefits with Additional Treatment
Furthermore, the presentation covered findings from the trial’s open-label extension, where all eligible patients continued their treatment. Notably, these participants received nebokitug for up to an additional 33 weeks after the initial phase. Results showed that the treatment remains safe and well-tolerated throughout this extended duration, providing sustained beneficial effects for patients battling PSC.
Comments from Chemomab's Leadership
Adi Mor, PhD, the CEO and co-founder of Chemomab, expressed excitement over the trial’s implications, particularly the significance of presenting at such a distinguished gathering. He acknowledged the critical need for new therapies to address the challenges PSC patients face daily. As the company gears up for a Phase 3 trial, there is optimism that nebokitug could soon lead the way as the first approved therapy for PSC.
Understanding Nebokitug and Its Development
Chemomab is at the forefront of expanding treatment options for fibrotic diseases. Nebokitug (CM-101), a pioneering monoclonal antibody, works by neutralizing the soluble protein CCL24, which has a known role in promoting fibrosis and inflammation. Its successful Phase 2 results are a testament to its potential. With positive data from four previous clinical trials under its belt, Chemomab is poised for significant advancements in the field of hepatology.
Future Directions
The design of the upcoming Phase 3 trial emphasizes a streamlined approval pathway focused on primary clinical endpoints. This significant step, combined with its Orphan Drug and Fast Track designations from the FDA, places nebokitug in a favorable position to address unmet needs in PSC treatment. As Chemomab progresses forward, the attention remains on transforming the landscape of care for patients suffering from this challenging condition.
Frequently Asked Questions
What is nebokitug?
Nebokitug (CM-101) is a dual activity monoclonal antibody developed by Chemomab that targets CCL24, showing promise in treating conditions like primary sclerosing cholangitis.
What were the key findings from the SPRING trial?
The SPRING trial data indicated that nebokitug is safe and well-tolerated, demonstrating significant improvement in biomarkers linked to PSC progression over a treatment period of 48 weeks.
Who presented the SPRING trial results?
Dr. Douglas Thorburn presented the SPRING trial results at the BSG Live’25 conference, highlighting the benefits of nebokitug for patients with primary sclerosing cholangitis.
What is the significance of the Phase 3 trial for nebokitug?
The Phase 3 trial is crucial as it seeks to establish a clear pathway for nebokitug to gain regulatory approval as the first effective therapy for PSC.
What does the future hold for Chemomab and nebokitug?
Chemomab aims to initiate the Phase 3 trial soon, building on encouraging data and striving to be a leader in the treatment of fibro-inflammatory conditions like PSC.
